6-[1-(4-methanesulfonyl-phenyl)-2-(tetrahydropyran-4-yl)ethyl]-5H-pyrrolo[2,3-b]pyrazine | 1313810-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡嗪类
• 英文名称: 6-[1-(4-methanesulfonyl-phenyl)-2-(tetrahydropyran-4-yl)ethyl]-5H-pyrrolo[2,3-b]pyrazine
• 英文别名: 6-[1-(4-methylsulfonylphenyl)-2-(oxan-4-yl)ethyl]-5H-pyrrolo[2,3-b]pyrazine
• CAS: 1313810-48-8
• 化学式: C₂₀H₂₃N₃O₃S
• 分子量: 385.487
• InChiKey: HSPXVMCPKJWVHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  93.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] FUSED NITROGEN HETEROCYCLIC COMPOUNDS, PROCESS OF PREPARATION AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AZOTÉS CONDENSÉS, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS
  申请人：ADVINUS THERAPEUTICS PRIVATE LTD

  公开号：WO2011080755A1

  公开（公告）日：2011-07-07

  Fused nitrogen heterocyclic compounds, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof, useful as Glucokinase activators or modulators, which are beneficial for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, such as diabetes, metabolic syndrome, and/or diabetes-related complications including retinopathy, nephropathy, neuropathy, ischemic heart disease, arteriosclerosis, β-cell dysfunction, and as therapeutic and/or prophylactic agents for obesity are disclosed. The invention also relates to process of preparation of the fused nitrogen heterocyclic compounds.

  含有融合氮杂环化合物、其立体异构体、互变异构体、前药、药用可接受的盐、多晶型、溶剂合物及其制剂，可用作葡萄糖激酶激活剂或调节剂，对于预防、管理、治疗、控制疾病的进展，或辅助治疗疾病和/或医疗状况，其中激活葡萄糖激酶将有益，如糖尿病、代谢综合征以及与糖尿病相关的并发症，包括视网膜病变、肾病、神经病变、缺血性心脏病、动脉硬化、β-细胞功能障碍，以及用作治疗和/或预防肥胖的治疗和/或预防剂。该发明还涉及融合氮杂环化合物的制备方法。